Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.51 +0.28 (+1.16%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
What's going on in today's session: S&P500 most active stocks
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Down 36%, Is Moderna a Buy on the Dip?
Via The Motley Fool
Pfizer Stock Climbs Pre-Market On Bladder Cancer Trial Success: Retail Digests Data Ahead Of Q1 Print
Pfizer highlighted positive late-stage results for its experimental bladder cancer drug, sasanlimab, as it looks to strengthen its oncology portfolio and offset losses from recent setbacks in its... 
Via Stocktwits
Topics Intellectual Property
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Via The Motley Fool
Topics Artificial Intelligence Energy
Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Government World Trade
The Week Ahead: PCE Inflation Data And Big Tech Earnings In Focus
Markets brace for crucial week with Big Tech earnings, Trump's 100-day milestone, and key economic data as trade concerns linger. 
Via Talk Markets
Topics Economy Government Stocks / Equities
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
Investors have been waiting nearly a decade to score a good deal on this healthcare star. 
Via The Motley Fool
Topics Economy Government
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout
After the closing bell, Merck said the two parties were discussing a deal at around $47 per share. 
Via Stocktwits
Most active S&P500 stocks in Thursday's session
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity. 
Via Chartmill
Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform
Guardant Health partners with Pfizer to support oncology drug development using smart liquid biopsy tech and expand testing access in China. 
Via Benzinga
5 All-Weather Dividend Stocks to Buy Right Now
Via The Motley Fool
Topics Economy
2 No-Brainer Stocks to Buy With Less Than $30
Via The Motley Fool
Topics Intellectual Property
3 Reasons VTRS is Risky and 1 Stock to Buy Instead
Viatris’s stock price has taken a beating over the past six months, shedding 33% of its value and falling to $7.69 per share. This was partly due to its softer quarterly results and might have... 
Via StockStory
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
Via The Motley Fool
Topics Government Stocks World Trade
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial
The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy. 
Via Stocktwits
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
Via Benzinga
Pfizer Declares Second-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Looking for the most active stocks in the S&P500 index on Wednesday?
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Wednesday and discover the stocks that are dominating the trading activity and setting the pace... 
Via Chartmill
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway. 
Via Benzinga
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
From Pfizer Inc.
Via Business Wire
Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers
The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data. 
Via Stocktwits
Topics Government
3 of Wall Street’s Favorite Stocks Walking a Fine Line
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
2 High-Yield Dividend Stocks to Buy for Passive Income
Via The Motley Fool
Topics Retirement
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients. 
Via MarketBeat
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug?
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.